Literature DB >> 27009803

Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting.

Yaakov Cass1, Thomas H Connor2, Alexander Tabachnik3.   

Abstract

Introduction With the growing number of oral targeted therapies being approved for use in cancer therapy, the potential for long-term administration of these drugs to cancer patients is expanding. The use of these drugs in the home setting has the potential to expose family members and caregivers to them either through direct contact with the drugs or indirectly by exposure to the parent compounds and/or their active metabolites in contaminated patients' waste. Methods A systematic literature review was performed and the known adverse health effect of 32 oral targeted therapeutics is summarized. In particular, the carcinogenicity, genotoxicity, and embryo-fetal toxicity, along with the route of excretion were evaluated. Results Carcinogenicity testing has not been performed on most of the oral targeted therapeutics and the genotoxicity data are mixed. However, the majority of these drugs exhibit adverse reproductive effects, some of which are severe. Currently, available data does not permit the possibility of a health hazard from inappropriate handling of drugs and contaminated patients waste to be ignored, especially in a long-term home setting. Further research is needed to understand these issues. Conclusions With the expanding use of targeted therapies in the home setting, family members and caregivers, especially those of reproductive risk age, are, potentially at risk. Overall basic education and related precautions should be taken to protect family members and caregivers from indirect or direct exposure from these drugs. Further investigations and discussion on this subject are warranted.

Entities:  

Keywords:  Oral antineoplastic medications; home setting; safe handling; targeted therapies

Mesh:

Substances:

Year:  2016        PMID: 27009803      PMCID: PMC5628499          DOI: 10.1177/1078155216637217

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  148 in total

1.  Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

Authors:  Mario E Lacouture; Kathryn O'Reilly; Neal Rosen; David B Solit
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Occupational exposures among nurses and risk of spontaneous abortion.

Authors:  Christina C Lawson; Carissa M Rocheleau; Elizabeth A Whelan; Eileen N Lividoti Hibert; Barbara Grajewski; Donna Spiegelman; Janet W Rich-Edwards
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

3.  A dramatic fetal outcome following transplacental transfer of dasatinib.

Authors:  Paul Berveiller; Annalisa Andreoli; Olivier Mir; Olivia Anselem; Anne-Lise Delezoide; Hélène Sauvageon; Nicolas Chapuis; Vassilis Tsatsaris
Journal:  Anticancer Drugs       Date:  2012-08       Impact factor: 2.248

4.  Dual roles of PARP-1 promote cancer growth and progression.

Authors:  Matthew J Schiewer; Jonathan F Goodwin; Sumin Han; J Chad Brenner; Michael A Augello; Jeffry L Dean; Fengzhi Liu; Jamie L Planck; Preethi Ravindranathan; Arul M Chinnaiyan; Peter McCue; Leonard G Gomella; Ganesh V Raj; Adam P Dicker; Jonathan R Brody; John M Pascal; Margaret M Centenera; Lisa M Butler; Wayne D Tilley; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Discov       Date:  2012-09-19       Impact factor: 39.397

Review 5.  Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.

Authors:  Siu-Fun Wong; Hamid Mirshahidi
Journal:  Ann Pharmacother       Date:  2011-06-13       Impact factor: 3.154

6.  Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.

Authors:  Richat Abbas; Stephan Chalon; Cathie Leister; Myriam El Gaaloul; Daryl Sonnichsen
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-30       Impact factor: 3.333

Review 7.  Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

Authors:  Arpita Shah; Abhishek Mangaonkar
Journal:  Ann Pharmacother       Date:  2015-07-16       Impact factor: 3.154

Review 8.  Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.

Authors:  Daniel J Crona; Meredith D Keisler; Christine M Walko
Journal:  Ann Pharmacother       Date:  2013-11-01       Impact factor: 3.154

Review 9.  Dermatological adverse events from BRAF inhibitors: a growing problem.

Authors:  Viswanath Reddy Belum; Alyssa Fischer; Jennifer Nam Choi; Mario E Lacouture
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

Review 10.  Vandetanib for the treatment of medullary thyroid carcinoma.

Authors:  Maryann R Cooper; Soo Yun Yi; Wael Alghamdi; Daniel J Shaheen; Michael Steinberg
Journal:  Ann Pharmacother       Date:  2013-11-14       Impact factor: 3.154

View more
  4 in total

1.  Recommendations for the safe use and handling of oral anticancer drugs in community pharmacy: A pan-Canadian consensus guideline.

Authors:  Kathy Vu; Philip Emberley; Erika Brown; Rick Abbott; Justin J Bates; Venetia Bourrier; Kathryn Djordjevic; Julie Greenall; Mova Leung; Mark Pasetka; Louise Paquet; Heather Logan
Journal:  Can Pharm J (Ott)       Date:  2018-05-16

Review 2.  Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.

Authors:  Christine Roussel; Kristine L Witt; Peter B Shaw; Thomas H Connor
Journal:  Mutat Res Rev Mutat Res       Date:  2017-08-24       Impact factor: 5.657

3.  Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations.

Authors:  Gennaro A Paolella; Andrew D Boyd; Scott M Wirth; Sandra Cuellar; Neeta K Venepalli; Stephanie Y Crawford
Journal:  Pharmacy (Basel)       Date:  2018-03-08

Review 4.  Guidelines for safe handling of hazardous drugs: A systematic review.

Authors:  Mari A Bernabeu-Martínez; Mateo Ramos Merino; Juan M Santos Gago; Luis M Álvarez Sabucedo; Carmina Wanden-Berghe; Javier Sanz-Valero
Journal:  PLoS One       Date:  2018-05-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.